These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 3948766)

  • 21. Comparison of the physicochemical properties of uterine nuclear estrogen receptors bound to estradiol or 4-hydroxytamoxifen.
    Attardi B; Happe HK
    Endocrinology; 1986 Aug; 119(2):904-15. PubMed ID: 3732150
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acceptor sites for the oestrogen receptor in hen oviduct chromatin.
    Ruh TS; Spelsberg TC
    Biochem J; 1983 Mar; 210(3):905-12. PubMed ID: 6870810
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antagonism to estradiol in the mouse: reduced entry of receptors complexed with 4-hydroxytamoxifen into a Mg2+-soluble chromatin fraction.
    Pavlik EJ; van Nagell JR; Nelson K; Gallion H; Donaldson ES; Kenady DE; Baranowska-Kortylewicz J
    Endocrinology; 1986 May; 118(5):1924-34. PubMed ID: 2422013
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An evaluation of the role of antiestrogen-binding sites in mediating the growth modulatory effects of antiestrogens: studies using t-butylphenoxyethyl diethylamine, a compound lacking affinity for the estrogen receptor.
    Sheen YY; Simpson DM; Katzenellenbogen BS
    Endocrinology; 1985 Aug; 117(2):561-4. PubMed ID: 4017947
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth.
    Coezy E; Borgna JL; Rochefort H
    Cancer Res; 1982 Jan; 42(1):317-23. PubMed ID: 7053859
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Binding of [3H]triamcinolone acetonide-receptor complexes to chromatin from the B-cell leukemia line, BCL1.
    Ruh MF; Singh RK; Bellone CJ; Ruh TS
    Biochim Biophys Acta; 1985 Jan; 844(1):24-33. PubMed ID: 3871335
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Extensive in situ activation of nuclear estrogen receptors after exposure of murine uteri to [3H]estradiol or [3H]4-hydroxytamoxifen.
    Pavlik EJ; Nelson K; van Nagell JR; Donaldson ES; Walden ML; Gallion H; Kenady DE
    Endocrinology; 1987 Apr; 120(4):1608-14. PubMed ID: 3830064
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Triphenylethylene antiestrogen-binding sites in cockerel liver nuclei: evidence for an endogenous ligand.
    Murphy PR; Butts C; Lazier CB
    Endocrinology; 1984 Jul; 115(1):420-6. PubMed ID: 6734522
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells.
    Marsaud V; Gougelet A; Maillard S; Renoir JM
    Mol Endocrinol; 2003 Oct; 17(10):2013-27. PubMed ID: 12855746
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiestrogen pharmacology and mechanism of action.
    Katzenellenbogen BS; Miller MA; Eckert RL; Sudo K
    J Steroid Biochem; 1983 Jul; 19(1A):59-68. PubMed ID: 6887873
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A new antiestrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotropic effects in mice and rats.
    Greenberger LM; Annable T; Collins KI; Komm BS; Lyttle CR; Miller CP; Satyaswaroop PG; Zhang Y; Frost P
    Clin Cancer Res; 2001 Oct; 7(10):3166-77. PubMed ID: 11595711
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
    Long BJ; Jelovac D; Thiantanawat A; Brodie AM
    Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The pure antiestrogen ICI 182,780 binds to a high-affinity site distinct from the estrogen receptor.
    Parisot JP; Hu XF; Sutherland RL; Wakeling A; Zalcberg JR; DeLuise M
    Int J Cancer; 1995 Aug; 62(4):480-4. PubMed ID: 7635575
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Estrone receptor formation during the processing of estradiol-receptor complex in MCF-7 cells.
    Hansen ER; Brooks SC
    Cancer Res; 1982 May; 42(5):1967-74. PubMed ID: 7066908
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Physicochemical and genetic evidence for specific antiestrogen binding sites.
    Faye JC; Jozan S; Redeuilh G; Baulieu EE; Bayard F
    Proc Natl Acad Sci U S A; 1983 Jun; 80(11):3158-62. PubMed ID: 6574477
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.
    Brünner N; Boysen B; Jirus S; Skaar TC; Holst-Hansen C; Lippman J; Frandsen T; Spang-Thomsen M; Fuqua SA; Clarke R
    Cancer Res; 1997 Aug; 57(16):3486-93. PubMed ID: 9270017
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of antiestrogen versus antiprogestin on transformed and nontransformed steroid receptors.
    Turner JW; Ruh MF; Ward DT; Ruh TS
    J Steroid Biochem Mol Biol; 1991 Feb; 38(2):197-203. PubMed ID: 2004041
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen.
    Bentrem D; Dardes R; Liu H; MacGregor-Schafer J; Zapf J; Jordan V
    Endocrinology; 2001 Feb; 142(2):838-46. PubMed ID: 11159857
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiestrogen action in breast cancer cells: modulation of proliferation and protein synthesis, and interaction with estrogen receptors and additional antiestrogen binding sites.
    Katzenellenbogen BS; Miller MA; Mullick A; Sheen YY
    Breast Cancer Res Treat; 1985; 5(3):231-43. PubMed ID: 4027393
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiestrogen interaction with estrogen receptors and additional antiestrogen binding sites in human breast cancer MCF-7 cells.
    Ahn MR; Sheen YY
    Arch Pharm Res; 1997 Dec; 20(6):579-85. PubMed ID: 18982263
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.